TY - JOUR
T1 - Modifiable Factors Associated With Copeptin Concentration
T2 - A General Population Cohort
AU - van Gastel, Maatje D. A.
AU - Meijer, Esther
AU - Scheven, Lieneke E.
AU - Struck, Joachim
AU - Bakker, Stephan J. L.
AU - Gansevoort, Ron T.
N1 - Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
PY - 2015/5
Y1 - 2015/5
N2 - Background: Vasopressin plays an important role in maintaining volume homeostasis. However, recent studies suggest that vasopressin also may play a detrimental role in the progression of chronic kidney disease. It therefore is of interest to identify factors that influence vasopressin concentration, particularly modifiable ones.Study Design: Cross-sectional analyses.Setting & Participants: Data used are from participants in a large general-population cohort study (Prevention of Renal and Vascular Endstage Disease [PREVEND]). Patients with a missing copeptin value (n = 888), nonfasting blood sample (n = 495), missing or assumed incorrect 24-hour urine collection (n = 388), or heart failure (n = 20) were excluded, leaving 6,801 participants for analysis.Factor: Identification of lifestyle-and diet-related factors that are associated with copeptin concentration.Outcomes: Copeptin concentration as surrogate for vasopressin.Measurements: Copeptin was measured by an immunoluminometric assay as a surrogate for vasopressin. Associations were assessed in uni- and multivariable linear regression analyses.Results: Median copeptin concentration was 4.7 (IQR, 2.9-7.6) pmol/L. When copeptin was studied as a dependent variable, the final stepwise backward model revealed associations with higher copeptin concentrations for lower 24-hour urine volume (P <0.001), higher sodium excretion (P <0.001), higher systolic blood pressure (P <0.001), current smoking (P <0.001), higher alcohol use (P <0.001), higher urea excretion (P = 0.003), lower potassium excretion (P = 0.002), use of glucose-lowering drugs (P = 0.02), higher body mass index (P <0.001), and higher plasma glucose level (P <0.001). No associations with copeptin concentration were found for C-reactive protein or use of diuretics or nondiuretic antihypertensives.Limitations: The cross-sectional study design does not allow firm conclusions on cause-effect relationships.Conclusions: Important lifestyle-and diet-related factors associated with copeptin concentration are current smoking, alcohol use, protein and potassium intake, and particularly fluid and sodium intake. These data form a rationale to investigate whether intervening on these factors results in a lower vasopressin concentration with concomitant beneficial renal effects. (C) 2015 by the National Kidney Foundation, Inc.
AB - Background: Vasopressin plays an important role in maintaining volume homeostasis. However, recent studies suggest that vasopressin also may play a detrimental role in the progression of chronic kidney disease. It therefore is of interest to identify factors that influence vasopressin concentration, particularly modifiable ones.Study Design: Cross-sectional analyses.Setting & Participants: Data used are from participants in a large general-population cohort study (Prevention of Renal and Vascular Endstage Disease [PREVEND]). Patients with a missing copeptin value (n = 888), nonfasting blood sample (n = 495), missing or assumed incorrect 24-hour urine collection (n = 388), or heart failure (n = 20) were excluded, leaving 6,801 participants for analysis.Factor: Identification of lifestyle-and diet-related factors that are associated with copeptin concentration.Outcomes: Copeptin concentration as surrogate for vasopressin.Measurements: Copeptin was measured by an immunoluminometric assay as a surrogate for vasopressin. Associations were assessed in uni- and multivariable linear regression analyses.Results: Median copeptin concentration was 4.7 (IQR, 2.9-7.6) pmol/L. When copeptin was studied as a dependent variable, the final stepwise backward model revealed associations with higher copeptin concentrations for lower 24-hour urine volume (P <0.001), higher sodium excretion (P <0.001), higher systolic blood pressure (P <0.001), current smoking (P <0.001), higher alcohol use (P <0.001), higher urea excretion (P = 0.003), lower potassium excretion (P = 0.002), use of glucose-lowering drugs (P = 0.02), higher body mass index (P <0.001), and higher plasma glucose level (P <0.001). No associations with copeptin concentration were found for C-reactive protein or use of diuretics or nondiuretic antihypertensives.Limitations: The cross-sectional study design does not allow firm conclusions on cause-effect relationships.Conclusions: Important lifestyle-and diet-related factors associated with copeptin concentration are current smoking, alcohol use, protein and potassium intake, and particularly fluid and sodium intake. These data form a rationale to investigate whether intervening on these factors results in a lower vasopressin concentration with concomitant beneficial renal effects. (C) 2015 by the National Kidney Foundation, Inc.
KW - Copeptin
KW - vasopressin
KW - general population cohort
KW - lifestyle
KW - diet
KW - fluid intake
KW - sodium intake
KW - modifiable factor
KW - kidney disease progression
KW - CHRONIC-RENAL-FAILURE
KW - URINARY ALBUMIN EXCRETION
KW - ARGININE-VASOPRESSIN
KW - KIDNEY-DISEASE
KW - SODIUM-INTAKE
KW - GLOMERULAR-FILTRATION
KW - PLASMA VASOPRESSIN
KW - DIABETES-MELLITUS
KW - CIGARETTE-SMOKING
KW - SURROGATE MARKER
U2 - 10.1053/j.ajkd.2014.10.009
DO - 10.1053/j.ajkd.2014.10.009
M3 - Article
C2 - 25500109
SN - 0272-6386
VL - 65
SP - 719
EP - 727
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 5
ER -